Special Issue

Medicinal Applications of the *Cannabis* Plant

Message from the Guest Editor

This Special Issue aims to provide a collective body of research specifically focused on the benefits and risks of conventional consumption of the *Cannabis* plant, rather than synthetic analogues and formulates commonly used in clinical trials. We are interested in both experimental and observational research designs, which are particularly useful for measuring the real-world effects of consuming the wide range of available plant strains and plant-derived products, which typically vary from batch-to-batch in their chemotypic properties due to the heterogenetic nature of all phytomedicines, including the *Cannabis* plant. Furthermore, there is also a need for a better understanding of how effects from *Cannabis* consumption vary by individual or subgroup (e.g., across biological, demographic, or health conditions) in order to guide more personalized therapeutic treatments. We are interested in scientific contributions from all fields of *Cannabis* research. We are particularly interested in researchers measuring the effects of consuming the natural *Cannabis* plant and derived products.

Guest Editor

Dr. Jacob M. Vigil

Department of Psychology, University of New Mexico, Albuquerque, NM 87131, USA

Deadline for manuscript submissions

closed (30 June 2021)

Medicines

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Hiroshi Sakagami
Meikai University Research Institute of Odontology (M-RIO), 1-1
Keyakidai, Sakado, Saitama 350-0283, Japan

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:
indexed within PubMed, PMC, CAPlus / SciFinder, and
other databases.

Rapid Publication:
manuscripts are peer-reviewed and a first decision is
provided to authors approximately 45 days after
submission; acceptance to publication is undertaken in 5.7
days (median values for papers published in this journal in
the first half of 2025).